Skip to content

Biohaven BHVN Gross Unrealized Gains

Gross Unrealized Gains at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's gross unrealized gains?
Biohaven (BHVN) reported gross unrealized gains of $2K in Q1 2026.
How has Biohaven's gross unrealized gains changed year-over-year?
Biohaven's gross unrealized gains decreased by 97.2% year-over-year, from $71K to $2K.
What is the long-term trend for Biohaven's gross unrealized gains?
Over 3 years (2022 to 2025), Biohaven's gross unrealized gains has grown at a 6.1% compound annual growth rate (CAGR), from $51K to $61K.